Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Navidea Biopharmaceuticals (NYSE:NAVB) Lymphoseek Moves Forward, Shorts On Alert

Lymphoseek® Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology

‒ Lymphoseek Successful in Sentinel Lymph Node Identification Compared With Pathology Gold Standard -

It really is just me.

This is where you (potential shareholder) ignore the day to day trading of a stock and make a decision. Is it worth it?

Your money, your choice.

I've been on my own for many plays as they near bottom. Navidia $NAVB is off the bottom of $1 now but reaches a pretty undercover audience. Why are they undercover? Because of the financing obtained through previous deals to move Navidea forward that have been unfavorable. Now, under new management, an inspiring new CEO and FDA support this is a bridge that science will put in the near past as new money is made aware of the science and benefit to patients.

$NAVB has quite the short interest position. I recommend anyone looking to do their own due diligence. I also recommend a look not only at the science that is being brought more into the light as a cutting edge option in a competitive industry. The shorts wouldn't want you to know the potential market cap so I'll simply leave that out. But take a look at the difference in patient benefit. That simple, and I'll leave the $$$ to speak for itself.

This is after all, a blog post. I like the science, and I like the potential added with the Manocept™ platform. Again, do your own DD.

In my opinion.

Disclosure: The author is long "NAVB".